BC Week In Review | Dec 15, 2014
Company News

Zydus sales and marketing update

Zydus launched Exemptia , a biosimilar of adalimumab, in India to treat autoimmune disorders including rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis. Eisai Co. Ltd. (Tokyo:4523, Tokyo, Japan) and Abbott Laboratories (NYSE:ABT,...
Items per page:
1 - 1 of 1